您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Latanoprost(free acid)-d4
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Latanoprost(free acid)-d4
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Latanoprost(free acid)-d4图片
规格:98%
分子量:394.5
包装与价格:
包装价格(元)
50ug电议
100ug电议
500ug电议
1mg电议

产品介绍
Internal standard for the quantification of latanoprost (free acid)
货号:ajcx22784
CAS:1224443-47-3
分子式:C23H30D4O5
分子量:394.5
溶解度:DMF: 50 mg/ml,DMSO: 50 mg/ml,Ethanol: 100 mg/ml,PBS (pH 7.2): .5 mg/ml
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Latanoprost (free acid)-d4(Lat-FA-d4) contains four deuterium atoms at the 3, 3, 4, and 4 positions. It is intended for use as an internal standard for the quantification of Lat-FA by GC-or LC-mass spectrometry. Latanoprost is an F-series prostaglandin (PG) analog which has been approved for use as an ocular hypotensive drug.1It is the isopropyl ester of a PGFanalog containing an aromatic group (17-phenyl) in the ω-chain. As an isopropyl ester, latanoprost acts as a prodrug which is converted to Lat-FA by endogenous esterase enzymes. Lat-FA is a potent FP receptor agonist with an EC50value of 3.6 nM for human FP receptors, which is twice the potency of PGFand more than 200 times more potent latanoprost.2The efficacy of PG analog esters for the treatment of glaucoma correlates closely with the FP receptor binding affinity of the free acid.3However, Lat-FA is more irritating and less effective than the prodrug latanoprost when applied directly to the eyes of human glaucoma patients.4


1.Stjernschantz, J., and Resul, B.Phenyl substituted prostaglandin analogs for glaucoma treatmentDrugs of the Future17691-704(1992) 2.Abramovitz, M., Adam, M., Boie, Y., et al.The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogsBiochim. Biophys. Acta1483(2)285-293(2000) 3.Camras, C.B., Alm, A., Watson, P., et al.Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patientsOphthalmology1031916-1924(1996) 4.Sugamoto, K., Matsushita, Y.i., and Matsui, T.Facile and general method for preparation of (E)-4-hydroxy-2-alkenalsLipids32903-905(1997)